Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

NRXS

Neuraxis Inc

Dec 12 • 10:35AM ET

2.83

Dollar change +0.25
Percentage change 9.69	%

Healthcare • Biotechnology • USA • AMEX

Peers: MDT BSX ABT SYK ISRG ZBH RMD EW ALGN BIO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.81	Insider Own	52.13%	Shs Outstand	6.98M	Perf Week	6.39%
Market Cap	19.75M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.34M	Perf Month	-10.45%
Income	-12.15M	PEG	-	EPS next Q	-	Inst Own	4.59%	Short Float	0.17%	Perf Quarter	-8.71%
Sales	2.46M	P/S	8.03	EPS this Y	-	Inst Trans	-	Short Ratio	0.34	Perf Half Y	-3.42%
Book/sh	-0.26	P/B	-	EPS next Y	-	ROA	-1017.73%	Short Interest	0.01M	Perf Year	1.07%
Cash/sh	0.04	P/C	75.97	EPS next 5Y	-	ROE	-	52W Range	2.00 - 3.89	Perf YTD	5.99%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-27.25%	Beta	4.22
Dividend TTM	-	Quick Ratio	0.23	Sales past 5Y	10.42%	Gross Margin	87.06%	52W Low	41.50%	ATR (14)	0.35
Dividend Ex-Date	-	Current Ratio	0.24	EPS Y/Y TTM	30.46%	Oper. Margin	-297.84%	RSI (14)	48.18	Volatility	15.60% 12.54%
Employees	19	Debt/Eq	-	Sales Y/Y TTM	-3.36%	Profit Margin	-494.73%	Recom	1.00	Target Price	7.50
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	73.65%	Payout	-	Rel Volume	0.01	Prev Close	2.58
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	39.62%	Earnings	Nov 12 BMO	Avg Volume	16.80K	Price	2.83
SMA20	-5.34%	SMA50	-2.40%	SMA200	-7.11%	Trades		Volume	44	Change	9.69%

Dec-10-24 09:00AM	NeurAxis Inc. Announces FDA 510(k) Clearance of RED for Testing and Evaluation of Patients with Chronic Constipation (GlobeNewswire) -7.48%
Nov-12-24 08:10AM	NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues (GlobeNewswire) +26.40%
Nov-05-24 09:00AM	NeurAxis to Host Third Quarter 2024 Results and Business Update Call on Tuesday, November 12, 2024 (GlobeNewswire)
Nov-04-24 09:00AM	NeurAxis Receives New FDA 510(K) Clearance for IB-Stim, Expanding its Addressable Market (GlobeNewswire)
Oct-29-24 09:00AM	NeurAxis Announces Capital Blue Cross Medical Policy Coverage for PENFS, effective October 1st 2024 (GlobeNewswire)
09:00AM	Loading…
Oct-22-24 09:00AM	NeurAxis Announces New CPT Category I Code for Percutaneous Electrical Nerve Field Stimulation (GlobeNewswire) +5.07%
Sep-19-24 09:00AM	NeurAxis to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 (GlobeNewswire)
Aug-27-24 09:00AM	NeurAxis Announces Geisinger Health Plan Medical Policy Coverage for PENFS, Effective September 15 2024 (GlobeNewswire)
Aug-13-24 09:00AM	NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024 (GlobeNewswire)
Aug-09-24 08:00AM	NeurAxis Reports Second Quarter 2024 Financial Results (GlobeNewswire) +9.12%
Aug-05-24 09:00AM	NeurAxis to Host Second Quarter 2024 Results and Business Update Call on Friday, August 9, 2024 (GlobeNewswire) -17.61%
Jun-07-24 09:00AM	NeurAxis Announces New Submission to the FDA for the Expansion of its IB-Stim Label; Provides Compliance with NYSE Guidelines on Audit Disclosure (GlobeNewswire)
May-22-24 08:00AM	NeurAxis Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-21-24 09:00AM	NeurAxis to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (GlobeNewswire)
May-16-24 09:00AM	NeurAxis Announces New Medical Policy Coverage For Nearly Six Million Lives in Florida (GlobeNewswire) +11.96%
04:30PM	Loading…
May-15-24 04:30PM	NeurAxis to Host First Quarter 2024 Results and Business Update Call on Wednesday, May 22, 2024 (GlobeNewswire)
Apr-23-24 09:00AM	NeurAxis Announces New Medical Policy Coverage in North Dakota (GlobeNewswire) -11.18%
Apr-12-24 08:44AM	NeurAxis, Inc. (NASDAQ:NRXS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-09-24 04:05PM	NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results (GlobeNewswire)
Apr-01-24 04:15PM	NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024 (GlobeNewswire)
Mar-27-24 09:00AM	NeurAxis Announces IB-Stim Results from a Large, Pediatric, Multi-Center Registry (GlobeNewswire)
Mar-11-24 09:00AM	NeurAxis Announces Highmark BCBS Policy Coverage (GlobeNewswire)
Mar-04-24 09:00AM	NeurAxis Announces Blue Cross and Blue Shield of Kansas City Policy Coverage (GlobeNewswire) +8.82%
Feb-27-24 11:00AM	NeurAxis to Present at Oppenheimer 34th Annual Healthcare MedTech & Services Conference (GlobeNewswire)
Jan-31-24 09:00AM	NeurAxis Appoints Timothy Henrichs as Chief Financial Officer (GlobeNewswire)
Dec-20-23 09:00AM	NeurAxis, Inc. Issues Letter to Shareholders from Brian Carrico, President and Chief Executive Officer (GlobeNewswire)
Nov-20-23 05:30PM	NeurAxis Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-15-23 09:00AM	NeurAxis Announces CareFirst BCBS Policy Coverage (GlobeNewswire) +14.17%
Nov-14-23 09:00AM	NeurAxis Secures $3 Million Financing (GlobeNewswire)
Nov-08-23 09:00AM	NeurAxis Signs Exclusive Option Agreement with University of Michigan for Innovative Gastrointestinal Device (GlobeNewswire)
09:00AM	Loading…
Sep-26-23 09:00AM	NeurAxis Announces Results of Comparative Study of IB-Stim and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders (GlobeNewswire)
Sep-21-23 08:00AM	NeurAxis Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Sep-13-23 09:00AM	NeurAxis to Present at the Gilmartin Group Emerging Growth Showcase (GlobeNewswire) +7.87%
Sep-12-23 10:15AM	EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome (Benzinga) -16.92%
09:00AM	NeurAxis Announces Publication of Prospective Study Showing IB-Stim Improves Quality of Life of Adolescents with IBS (GlobeNewswire)
Aug-29-23 09:00AM	NeurAxis Highlights Pediatric Post-Concussion Clinical Study (GlobeNewswire)
Aug-24-23 09:00AM	NeurAxis Highlights Strength of its Board of Directors (GlobeNewswire) -10.15%
Aug-22-23 09:00AM	NeurAxis Highlights Two Independent Studies Showing Benefits of IB-Stim in Adolescents Involving the Gut Microbiome (GlobeNewswire) +16.50%
Aug-17-23 09:02AM	NeurAxis Announces Over $8 Million in IB-Stim Revenue (GlobeNewswire)
Aug-15-23 09:00AM	NeurAxis Announces Positive University of Michigan IB-Stim Cost Effectiveness Study at ANMS 2023 (GlobeNewswire)
Aug-11-23 09:30AM	Goldman Small Cap Research Publishes New Research Report on NeurAxis, Inc. (ACCESSWIRE)
Aug-10-23 09:00AM	NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin (GlobeNewswire)
09:00AM	Exchange Listing Client, Neuraxis, Inc., Successfully Completes Its Initial Public Offering and NYSE Listing (GlobeNewswire)
Aug-09-23 10:00AM	NeurAxis Announces Pricing of Initial Public Offering (GlobeNewswire)

NeurAxis, Inc. develops neuromodulation therapies to address chronic and debilitating conditions in children. Its product IB-Stim is a non-surgical device that works by sending gentle electrical impulses into cranial nerve bundles located in the ear. The company was founded by Gary Peterson and Christopher Robin Brown in 2011 and is headquartered in Carmel, IN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hannasch Brian	10% Owner	Dec 28 '23	Sale	2.61	76	198	532,901	Jan 23 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NRXS

Neuraxis Inc

Upgrade your FINVIZ experience